A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.

Nat Commun · 2022 · PMC9482645 · PMID 36115850

Europe PMC DOI

hedged sentence

0.2630

closest p · 5.3× alpha

0.2630

boldest claim

The sentences

did not reach statistical significanceP = 0.2630not close (p > 0.1)

A similar trend of higher nAb titers favoring the short interval was also identified in the homologous ChAdOx1 group at day 10 ± 3 though the difference of GMTs did not reach statistical significance at day 28 ± 3 (134.4 IU/mL versus 98.0 IU/mL, P = 0.2630, Fig. 4 and Supplementary Table 6 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.